Reply to J. Bergquist et al and T.-Y. Lai et al

Affiliations

¹ Ali A. Mokdad, Rebecca M. Minter, Hong Zhu, John C. Mansour, Michael A. Choti, and Patricio M. Polanco, University of Texas Southwestern Medical Center, Dallas, TX.

Comment

Ali A Mokdad et al. J Clin Oncol. 2017.

. 2017 May 10;35(14):1624-1625.

doi: 10.1200/JCO.2016.71.3891. Epub 2017 Jan 30.

¹ Ali A. Mokdad, Rebecca M. Minter, Hong Zhu, John C. Mansour, Michael A. Choti, and Patricio M. Polanco, University of Texas Southwestern Medical Center, Dallas, TX.

No abstract available

Comment on

Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA, Polanco PM. Mokdad AA, et al. J Clin Oncol. 2017 Feb 10;35(5):515-522. doi: 10.1200/JCO.2016.68.5081. Epub 2016 Sep 30. J Clin Oncol. 2017. PMID: 27621388
Patient Selection for Neoadjuvant Therapy in Early-Stage Pancreatic Cancer.
Bergquist JR, Shubert CR, Storlie CB, Habermann EB, Truty MJ. Bergquist JR, et al. J Clin Oncol. 2017 May 10;35(14):1622-1623. doi: 10.1200/JCO.2016.71.2315. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135141 No abstract available.
Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction.
Lai TY, Hu YW. Lai TY, et al. J Clin Oncol. 2017 May 10;35(14):1623. doi: 10.1200/JCO.2016.71.2273. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135147 No abstract available.